| Trial ID: | L5055 |
| Source ID: | NCT01915264
|
| Associated Drug: |
Acarbose/Metformin (Glucobay M, Bay81-9783)
|
| Title: |
GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice
|
| Acronym: |
GLORY
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Acarbose/Metformin (Glucobay M, BAY81-9783)
|
| Outcome Measures: |
Primary: Incidence of severe hypoglycemia or documented symptomatic or asymptomatic hypoglycemic events reported as adverse events, 24 weeks | Secondary: Incidence of adverse events other than hypoglycemia reported, 24 weeks|Mean change in HbA1c level, baseline and 24 weeks|Mean change in fasting blood sugar, baseline and 24 weeks|Mean change in postprandial blood sugar, baseline and 24 weeks|Mean change in body weight, baseline and 24 weeks|Mean change in serum LDL(low-density lipoprotein) cholesterol, baseline and 24 weeks|Mean change in serum triglyceride, baseline and 24 weeks|Mean change in serum HDL (High density lipoproteins) cholesterol, baseline and 24 weeks|Change in percent satisfaction to the therapy from baseline as measured by 5 point satisfaction scale, baseline and 24 weeks|Number of patient with adverse event (Tolerability), Baseline and 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: Bayer
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
0
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2015-08
|
| Completion Date: |
2017-03
|
| Results First Posted: |
|
| Last Update Posted: |
2016-04-25
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01915264
|
